AR127584A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR127584A1
AR127584A1 ARP220103036A ARP220103036A AR127584A1 AR 127584 A1 AR127584 A1 AR 127584A1 AR P220103036 A ARP220103036 A AR P220103036A AR P220103036 A ARP220103036 A AR P220103036A AR 127584 A1 AR127584 A1 AR 127584A1
Authority
AR
Argentina
Prior art keywords
salt
compound
formula
pharmaceutically acceptable
disease
Prior art date
Application number
ARP220103036A
Other languages
English (en)
Inventor
David Cousin
Oscar Barba
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Publication of AR127584A1 publication Critical patent/AR127584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a compuestos de fórmula (1a) y a su uso en el tratamiento o prevención de una enfermedad inflamatoria, una enfermedad asociada con una respuesta inmunitaria indeseable, cáncer, obesidad, una enfermedad diabética o un trastorno de la sangre, en donde RA, RB, RC y RD, X, Y¹, Y², Y³, Z¹, Z² y m son como se define en la presente. Reivindicación 61: Una composición farmacéutica que comprende un compuesto, sal y/o solvato aceptable desde el punto de vista farmacéutico de este, de acuerdo con una cualquiera de las reivindicaciones 1 a 60, y uno o más portadores o diluyentes aceptables desde el punto de vista farmacéutico. Reivindicación 65: Un método para tratar o prevenir una enfermedad, trastorno o afección asociada con la función de PK, en particular PKM2 y/o PKLR, que comprende administrar un compuesto, sal y/o solvato aceptable desde el punto de vista farmacéutico de este de acuerdo con una cualquiera de las reivindicaciones 1 a 60 o una composición farmacéutica de acuerdo con la reivindicación 61. Reivindicación 107: Un proceso para preparar un compuesto de fórmula (1a) como se describe en una cualquiera de las reivindicaciones 1 a 60, o una sal, tal como una sal y/o solvato aceptable desde el punto de vista farmacéutico de este, que comprende hacer reaccionar un compuesto de fórmula (2a-S); o una sal de este; con un compuesto de fórmula (3a-S); en donde RA, RB, RC, RD, Y¹, Y², Y³, Z¹, Z², X y m se definen de acuerdo con una cualquiera de las reivindicaciones 1 a 40, y LG² es un grupo saliente tal como halo (por ejemplo, cloro, bromo o yodo), OMs u OTs.
ARP220103036A 2021-11-05 2022-11-04 Compuestos novedosos AR127584A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21206793 2021-11-05
EP21216843 2021-12-22
EP22177827 2022-06-08

Publications (1)

Publication Number Publication Date
AR127584A1 true AR127584A1 (es) 2024-02-07

Family

ID=84331339

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103036A AR127584A1 (es) 2021-11-05 2022-11-04 Compuestos novedosos

Country Status (3)

Country Link
AR (1) AR127584A1 (es)
TW (1) TW202325288A (es)
WO (1) WO2023079294A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024095012A1 (en) 2022-11-04 2024-05-10 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078172A1 (en) * 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN103833646A (zh) * 2014-02-28 2014-06-04 广东工业大学 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用
WO2020167976A1 (en) 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
US20220242850A1 (en) * 2019-07-30 2022-08-04 Janssen Pharmaceutica Nv Phthalazin-1-one derivatives useful as grk2 inhibitors
CN112156095A (zh) * 2020-10-27 2021-01-01 兰州大学 M2型丙酮酸激酶小分子激活剂及其应用

Also Published As

Publication number Publication date
WO2023079294A1 (en) 2023-05-11
TW202325288A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
AR127584A1 (es) Compuestos novedosos
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
AR118856A2 (es) Compuestos terapéuticos
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
IL278297B1 (en) Transmutable heterocyclic ptpn11 inhibitors
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CA2531543C (en) Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR059590A1 (es) Inhibidores de quinasa basados en la hidantoina
CN104610230A (zh) 用于治疗癌症的化合物
PT1089998E (pt) Derivados de epotilona e sua síntese e utilização
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
CA2868002C (en) Antimicrobial agents
AR035071A1 (es) Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamento
WO2010084798A1 (ja) ３環性化合物
CN106794174A (zh) 治疗癌症的化合物
AR114679A1 (es) Compuestos heterocíclicos fungicidas
PE20212111A1 (es) Moduladores calpaina y usos terapeuticos de los mismos
JP2020520955A5 (es)
BR112016001876B1 (pt) Composto de benzoxaborol tricíclico, método de preparação e composição farmacêutica do mesmo
PE20200727A1 (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso
AR040968A1 (es) Bifenilcarboxamidas sustituidas con n- aril piperidina, un metodo para su preparacion, composicion farmaceutica y proceso de preparacion
IL287119B2 (en) Bryostatin compounds and methods for their preparation